Scholarlink

Objective <p>To investigate the effects of Computerized Cognitive Remediation Therapy (CCRT) on cognitive function and blood biomarker levels in community-dwelling older adults with Mild Cognitive Impairment (MCI), and to provide objective evidence for evaluating the effectiveness of CCRT.</p> Methods <p>This randomized controlled trial included 68 participants who completed the intervention and were included in the final analysis (37 in the intervention group and 31 in the control group). The control group received health education, while the intervention group received both health education and a 12-week CCRT intervention. Cognitive function was assessed using the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) before and after the intervention. Plasma levels of glial fibrillary acidic protein (GFAP) and phosphorylated Tau181 (P-tau181) were also measured at baseline and post-intervention. Linear mixed-effects models and receiver operating characteristic (ROC) curve analyses were used to examine the effects of CCRT on cognitive function and biomarker levels, as well as the predictive value of biomarkers for cognitive improvement.</p> Results <p>After the 12-week intervention, the intervention group showed significantly greater improvements in MMSE and MoCA total scores compared to the control group (MMSE: <i>P</i> = 0.007; MoCA: <i>P</i> = 0.001). Significant improvements were also observed in memory (MMSE: <i>P</i> = 0.027), language (MMSE: <i>P</i> = 0.018; MoCA: <i>P</i> &lt; 0.001), and attention (MoCA: <i>P</i> &lt; 0.001). Plasma GFAP levels significantly decreased in the intervention group compared to the control group (<i>P</i> &lt; 0.001), while no significant difference was found in P-tau181 levels (<i>P</i> = 0.501). ROC curve analysis showed that a reduction in GFAP levels significantly predicted cognitive improvement in MCI patients (AUC = 0.805, <i>P</i> &lt; 0.001).</p> Conclusion <p>This study demonstrates that a 12-week CCRT intervention can significantly improve cognitive function and reduce GFAP levels in community-dwelling older adults with MCI. The change in GFAP is associated with cognitive improvement, suggesting its potential as an objective biomarker for evaluating intervention effectiveness.</p> Trial registration <p>Chinese Clinical Trial Registry，Trial Registration Number: ChiCTR2500107961，Registration Date: August 21, 2025.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A study on the effects of CCRT on cognitive function and blood biomarkers in community-dwelling older adults with MCI

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月19日

查看全文
  • Zhenkun Tan,
  • Junjiao Ping,
  • Haibo Zhang,
  • Ying Zhang,
  • Chuijia Kong,
  • Yingyu Lu,
  • Baofan Liu,
  • Tingyun Jiang,
  • Xinxia Liu

摘要

Objective

To investigate the effects of Computerized Cognitive Remediation Therapy (CCRT) on cognitive function and blood biomarker levels in community-dwelling older adults with Mild Cognitive Impairment (MCI), and to provide objective evidence for evaluating the effectiveness of CCRT.

Methods

This randomized controlled trial included 68 participants who completed the intervention and were included in the final analysis (37 in the intervention group and 31 in the control group). The control group received health education, while the intervention group received both health education and a 12-week CCRT intervention. Cognitive function was assessed using the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) before and after the intervention. Plasma levels of glial fibrillary acidic protein (GFAP) and phosphorylated Tau181 (P-tau181) were also measured at baseline and post-intervention. Linear mixed-effects models and receiver operating characteristic (ROC) curve analyses were used to examine the effects of CCRT on cognitive function and biomarker levels, as well as the predictive value of biomarkers for cognitive improvement.

Results

After the 12-week intervention, the intervention group showed significantly greater improvements in MMSE and MoCA total scores compared to the control group (MMSE: P = 0.007; MoCA: P = 0.001). Significant improvements were also observed in memory (MMSE: P = 0.027), language (MMSE: P = 0.018; MoCA: P < 0.001), and attention (MoCA: P < 0.001). Plasma GFAP levels significantly decreased in the intervention group compared to the control group (P < 0.001), while no significant difference was found in P-tau181 levels (P = 0.501). ROC curve analysis showed that a reduction in GFAP levels significantly predicted cognitive improvement in MCI patients (AUC = 0.805, P < 0.001).

Conclusion

This study demonstrates that a 12-week CCRT intervention can significantly improve cognitive function and reduce GFAP levels in community-dwelling older adults with MCI. The change in GFAP is associated with cognitive improvement, suggesting its potential as an objective biomarker for evaluating intervention effectiveness.

Trial registration

Chinese Clinical Trial Registry，Trial Registration Number: ChiCTR2500107961，Registration Date: August 21, 2025.